Pelthos Therapeutics Inc. Insider Trading

PTHS

⊜ Compare

Last 12 months

Insiders bought 1000K and sold 486K on the open market.

34% of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

+514K

1 buy · 13 sales

Under a 10b5-1 plan

34%

of the value sold

Insiders who bought / sold

1 / 5

executives and directors

Last open-market buy

Jun 2026

Jun 11, 2026

Get an email when PTHS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 2	Peter Greenleaf Director	Sold10b5-1 plan	797	$21.17	17K	3.3%	Form 4
Oct 2	Ezra M Friedberg Director	Sold10b5-1 plan	558	$20.72	12K	0.3%	Form 4
Oct 2	Matthew Pauls Director	Sold10b5-1 plan	786	$21.00	17K	5.5%	Form 4
Jul 2	Ezra M Friedberg Director	Sold10b5-1 plan 2 parts	558	$26.09 average	15K	0.3%	Form 4
Jul 2	Matthew Pauls Director	Sold10b5-1 plan 2 parts	786	$26.16 average	21K	5.2%	Form 4
Jul 2	Peter Greenleaf Director	Sold10b5-1 plan 2 parts	797	$26.14 average	21K	3.2%	Form 4
Jun 15	Ezra M Friedberg Director	Sold10b5-1 plan 2 parts	283	$27.29 average	8K	0.1%	Form 4
Jun 11	Todd C Davis Director	Bought 2 parts	35,948	$27.81 average	1000K	2.3%	Form 4
May 22	Knuettel Francis II CFO, Treas & Secty	SoldNo plan	1,500	$26.84	40K	3.5%	Form 4
Apr 2	Richard Malamut Director	Sold10b5-1 plan 2 parts	590	$20.91 average	12K	2.0%	Form 4
Apr 2	Ezra M Friedberg Director	Sold10b5-1 plan 2 parts	558	$20.91 average	12K	0.3%	Form 4
Apr 2	Matthew Pauls Director	Sold10b5-1 plan 2 parts	786	$20.92 average	16K	4.9%	Form 4
Apr 2	Peter Greenleaf Director	Sold10b5-1 plan 2 parts	797	$20.92 average	17K	3.1%	Form 4
Nov 25, 2025	Ezra M Friedberg Director	SoldNo plan 4 parts	10,000	$28.03 average	280K	7.4%	Form 4

Oct 210b5-1 plan
Peter Greenleaf
Director · sold 797 at $21.17
17K
3.3% of stake
Oct 210b5-1 plan
Ezra M Friedberg
Director · sold 558 at $20.72
12K
0.3% of stake
Oct 210b5-1 plan
Matthew Pauls
Director · sold 786 at $21.00
17K
5.5% of stake
Jul 210b5-1 plan
Ezra M Friedberg
Director · sold 558 at avg $26.09
15K
0.3% of stake
Jul 210b5-1 plan
Matthew Pauls
Director · sold 786 at avg $26.16
21K
5.2% of stake
Jul 210b5-1 plan
Peter Greenleaf
Director · sold 797 at avg $26.14
21K
3.2% of stake
Jun 1510b5-1 plan
Ezra M Friedberg
Director · sold 283 at avg $27.29
8K
0.1% of stake
Jun 11
Todd C Davis
Director · bought 35,948 at avg $27.81
1000K
2.3% of stake
May 22No plan
Knuettel Francis II
CFO, Treas & Secty · sold 1,500 at $26.84
40K
3.5% of stake
Apr 210b5-1 plan
Richard Malamut
Director · sold 590 at avg $20.91
12K
2.0% of stake
Apr 210b5-1 plan
Ezra M Friedberg
Director · sold 558 at avg $20.91
12K
0.3% of stake
Apr 210b5-1 plan
Matthew Pauls
Director · sold 786 at avg $20.92
16K
4.9% of stake
Apr 210b5-1 plan
Peter Greenleaf
Director · sold 797 at avg $20.92
17K
3.1% of stake
Nov 25, 2025No plan
Ezra M Friedberg
Director · sold 10,000 at avg $28.03
280K
7.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PTHS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with PTHS

CompareIntrinsic value

DTILPrecision Biosciences Inc.

$7.89+13.20%48

STROSutro Biopharma, Inc.

$9.94+4.52%10

EDITEditas Medicine Inc.

$2.73+5.00%40

VYGRVoyager Therapeutics Inc.

$1.87+2.19%10

CHRSCoherus Biosciences Inc.

$0.85+5.46%10

FENCFennec Pharmaceuticals Inc.

$10.35-3.27%40

CCCCC4 Therapeutics Inc.

$3.12-2.80%33

SGMOSangamo Therapeutics Inc.

$0.12-0.20%10

Spot a number that looks wrong? Check it in PTHS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PTHS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.